Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of understanding and complying with all aspects of the protocol.~* Signed Informed Consent.~* Capable of understanding the plasmapheresis information sheet and sign it.~* Healthy male or female volunteers, age 18 years or older.~* Women must have negative pregnancy test (human chorionic gonadotropin \[HCG\] based assay).~* Women must have sufficient methods of contraception (eg, intrauterine device, oral contraception, etc).~* No clinically relevant abnormalities in medical history and general physical examination.~* Standard health insurance.~Exclusion Criteria:~* Pregnancy or lactation.~* Tattoos within the last 3 months.~* Subject was treated therapeutically with fresh frozen plasma, blood, or plasma-derived products within the last 6 months.~* Hypersensitivity to blood products or plasma proteins.~* History of angioedema.~* History of coagulation or bleeding disorder or any other known abnormality affecting coagulation, fibrinolysis, or platelet function.~* Any clinically significant abnormal laboratory values.~* IgA deficiency.~* Seropositivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus type 1 or type 2 antibodies.~* Symptoms of a clinically relevant illness within 3 weeks before the first trial day.~* History of or suspected drug or alcohol abuse.~* Subjects currently participating in another clinical study.~* Any investigational medicinal product administration within the last 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Octaplas LG (Type: EXPERIMENTAL): Participants received 1200 mL of Octaplas LG intravenously once.
- Octaplas SD (Type: ACTIVE_COMPARATOR): Participants received 1200 mL of Octaplas SD intravenously once.

Based on this trial design, predict the completion outcome and termination type (if applicable).